← Back to all trials
Recruiting
NCT06849258
A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms
Conditions: Benign Prostatic Hyperplasia
Sex: Male
Ages: 45 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 215
Sponsor: Rivermark Medical
Location: Michael G Oefelein Clinical Trials Bakersfield California
Summary
The goal of this study is to determine the safety and effectiveness of the FloStent, a medical device used to treat men with symptoms of Benign Prostatic Hyperplasia, compared to sham (procedure without deployment of the FloStent). All participants will undergo a flexible cystoscopy and those randomized to the treatment arm will receive the FloStent, while those randomized to the sham arm will not receive the FloStent.
Eligibility Criteria
Inclusion Criteria:
* Male subjects \> 45 years of age who have symptomatic BPH
* International Prostate Symptom Score (IPSS) score \>13
* Peak urinary flow rate (Qmax): \>5 mL/sec and \125 mL
* Post-void residual (PVR) \10 ng/mL
* Bladder cancer or bladder stones
* Active urinary tract infection (UTI)
* Uncontrolled diabetes
* Part of a vulnerable population (cognitively challenged or are incarcerated)
Source: ClinicalTrials.gov (NCT06849258). StuddyBuddy aggregates publicly available trial information.